Dr. Allen W. Davidoff, Ph.D. Most recently acted as Chief Scientific officer of Stem Cell Therapeutics Corp. Overall, 10 years of drug development experience with a broad clinical and regulatory experience. Senior management experience in pharmaceutical R&D including 2 investigational new drug ("IND") applications or supplemental IND's, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 new drug applications. Including 2 years as Sen

Grace Jung, PhD (21 years of experience in drug discovery and development) was formerly Senior Director of Research (Chemistry) at Cardiome. During the 14 years at Cardiome, she led the chemistry team in the discovery of antiarrhythmic vernakalant and in process research efforts to devise a scalable manufacturing route for vernakalant. Before joining Cardiome, Grace spent 7 years at Boehringer Ingelheim (Laval, QC, Canada), where she was a medici

Brian Mangal, M.Sc. (12 years of clinical development experience), Formerly Director Biostatistics at Cardiome. Clinical development experience includes design, analysis and reporting of over 50 clinical trials, three FDA submissions, one TPD submission, a successful EMEA submission and numerous interactions with regulatory authorities, including participation in a successful advisory panel meeting for Vernakalant.  

Dr. Alan F. Moore, Ph.D. He has extensive clinical development experience and 23 years of senior management experience in pharmaceutical R&D with P&G during his esteemed career, he has completed 11 investigational new drug ("IND") applications or supplemental IND's, 15 phase I studies, 12 phase II studies, 7 phase III studies and 2 new drug applications. Most recently CEO of BetaStem Inc.